Ipilimumab in cancer patients:  the issue of early metabolic response.
Cyrus
C
Chargari
Sylvestre
S
Le Moulec
Gérald
G
Bonardel
Hervé
H
Foehrenbach
Lionel
L
Védrine
D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D003872:Dermatitis / Q000209:etiology; D019788:Fluorodeoxyglucose F18; D006801:Humans; D000074324:Ipilimumab; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D049268:Positron-Emission Tomography / Q000379:methods; D019275:Radiopharmaceuticals; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000074324:Ipilimumab; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18